SciELO - Scientific Electronic Library Online

 
vol.11 número1Intervalo QTc prolongado en pacientes de Clínica Médica: estudio multicéntricoFrecuencia de factores de riesgo para el desarrollo de prediabetes en el personal sanitario índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Revista Virtual de la Sociedad Paraguaya de Medicina Interna

versión On-line ISSN 2312-3893

Resumen

CABALLERO TORRES, Marlene Elizabeth et al. Monotherapy versus combination therapy as treatment of multidrug-resistant Acinetobacter baumannii infections. Rev. virtual Soc. Parag. Med. Int. [online]. 2024, vol.11, n.1, e11122413.  Epub 20-Jun-2024. ISSN 2312-3893.  https://doi.org/10.18004/rvspmi/2312-3893/2024.e11122413.

Introduction:

Acinetobacter baumannii is associated with high morbidity and mortality, longer hospital stays, and, therefore, a great health impact.

Objectives:

To compare the clinical response and survival using intravenous colistin as antibiotic treatment versus colistin combined with high doses of ampicillin/sulbactam in multidrug-resistant A. baumannii infections in the adult intensive care units of the National Hospital (Itauguá, Paraguay).

Materials and methods:

A retrospective cohort design was applied to analyze the clinical and laboratory response, 14-day survival, and mortality rate in patients treated with colistin five mg/kg/day as monotherapy versus combined colistin therapy five mg/kg/day plus ampicillin/sulbactam 9 grams four times a day. The variables were obtained from the clinical records of patients ≥18 years old infected with multidrug-resistant A. baumannii.

Results:

One hundred sixty-three patients were included, with a mean age of 50 ± 17 years, 61.96% male. Pneumonia associated with mechanical ventilation was present in 69.33%, bacteremia in 21.47%, ventriculitis in 5.52% and infections related to the central venous line in 3.68%. A cohort of 88 patients received monotherapy with intravenous colistin and another of 75 patients received combined therapy with intravenous colistin plus high doses of ampicillin/sulbactam. No differences were found in the APACHE II score between both cohorts. The cohort with combined treatment demonstrated statistically significant superiority by presenting clinical and laboratory improvement at 72 hours, less need for vasopressors, better survival at 14 days, and less nephrotoxicity. The overall mortality rate was 45.40%.

Conclusion:

The combined therapy of intravenous colistin with high doses of ampicillin/sulbactam in prolonged infusion was related to early clinical improvement, shorter time requiring vasopressors and mechanical ventilation, greater survival at 14 days, and less nephrotoxicity.

Palabras clave : Acinetobacter baumannii; colistin; ampicillin; sulbactam; bacterial drug resistance.

        · resumen en Español     · texto en Español     · Español ( pdf )